Children living with HIV/AIDS in the East Africa region will soon benefit from a new antiretroviral formulation developed by the Pharmaceutical Company Cipla in collaboration with the Drugs for Neglected Disease Initiative (DNDI) and approved by WHO in 2015 which is easier to administer and has a “friendly” taste.

The formulation containing the antiretroviral drugs ‘Lopinavir and Ritonavir will be in an oral pellet and will replace the syrup form of the same drugs with bitter taste used in treating pediatric HIV